Table 1.

Overview of some HCC targets.

Target	Gene Function	Current Clinical Drugs Targeting	Protein Half-life	References
VEGFR/VEGFR2	Angiogenesis	Sorafenib, Brivanib, Sunitinib, Cediranib, BIBF1120, Pazopanib, Regorafenib, E7080, TSU-68, Vandetanib, Ramucirumab, IMC-1121B	70 min	[5,15,21]
EGFR	Signal Transduction	Erlotinib, Cetuximab, Gefitinib, Lapatinib, Vandetanib	10 h	[5,16,21]
Bcr-ABL	Cell Proliferation	Destanib	40 h	[5,10,17,21]
MEK	Signal Transduction	AZD6244	6 h	[5,18,21]
PDGFR	Angiogenesis/Signal Transduction	Sorafenib, Brivanib, Linifanib, BIBF1120, Pazopanib, TSU-68	3 h	[5,19,21]